This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, Y. Articles by Terada, M. Search for Related Content PubMed PubMed Citation Articles by Yamada, Y. Articles by Terada, M.

p53 Gene Mutations in Gastric Cancer Metastases and in Gastric Cancer Cell Lines Derived from Metastases¹

Genetics Division [Y. Y., T. Y., T. Su., M. T.], Oncogene Division [K. H., T. Se.], Section of Studies on Metastasis [J. Y.], and Pathology Division [S. H.], National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104, and First Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634 [Y. Y., K. N., H. N.], Japan

Structural alterations of the p53 gene were investigated in tissue specimens of gastric and cervical cancers and in cell lines of gastric, esophageal, and cervical cancers, by polymerase chain reaction-single-strand conformation polymorphism analysis. Two of the four gastric cancer metastases and four of the eight cell lines originally established from gastric cancer metastases were found to have p53 gene alterations in the exon 5 to 11 region; point mutations and amino acid replacements were detected in a liver and an ovary metastasis at exon 7, in the TMK1 and MKN1 cell lines at exon 5, and in the OKAJIMA cell line at exon 10. The normal allele was not found in these cell lines. In the KATO-III cell line, gross deletion and rearrangement of the p53 gene were noted. However, no p53 mutations were identified in 19 primary lesions of gastric cancer, suggesting that the p53 gene abnormality preferentially occurs in the advanced stages of gastric cancer. In contrast to the gastric cancer, none of the 13 esophageal cancer cell lines, including two cell lines established from metastases, and none of the four cervical cancer cell lines showed any aberration in exons 5 to 11 of the p53 gene. During the course of the study, a novel polymorphism in intron 7 of the p53 gene was found, which can be recognized by restriction enzyme digestions of the polymerase chain reaction product.

¹ This study was supported in part by Grants-in-Aid from the Ministry of Health and Welfare for a Comprehensive 10-Year Strategy for Cancer Control, Japan.

² To whom requests for reprints should be addressed.

Received 8/10/90. Accepted 8/20/91.

This article has been cited by other articles:

				R. Hino, H. Uozaki, Y. Inoue, Y. Shintani, T. Ushiku, T. Sakatani, K. Takada, and M. Fukayama Survival Advantage of EBV-Associated Gastric Carcinoma: Survivin Up-regulation by Viral Latent Membrane Protein 2A Cancer Res., March 1, 2008; 68(5): 1427 - 1435. [Abstract] [Full Text] [PDF]

				T. Terui, K. Murakami, R. Takimoto, M. Takahashi, K. Takada, T. Murakami, S. Minami, T. Matsunaga, T. Takayama, J. Kato, et al. Induction of PIG3 and NOXA through Acetylation of p53 at 320 and 373 Lysine Residues as a Mechanism for Apoptotic Cell Death by Histone Deacetylase Inhibitors Cancer Res., December 15, 2003; 63(24): 8948 - 8954. [Abstract] [Full Text] [PDF]

				H. L. Yang, Y. B. Dong, M. J. Elliott, T. J. Liu, and K. M. McMasters Caspase Activation and Changes in Bcl-2 Family Member Protein Expression Associated with E2F-1-mediated Apoptosis in Human Esophageal Cancer Cells Clin. Cancer Res., April 1, 2000; 6(4): 1579 - 1589. [Abstract] [Full Text]

				M. Yoshida, Y. Maehara, and K. Sugimachi MST-16, a Novel Bis-dioxopiperazine Anticancer Agent, Ameliorates Doxorubicin-induced Acute Toxicity While Maintaining Antitumor Efficacy Clin. Cancer Res., December 1, 1999; 5(12): 4295 - 4300. [Abstract] [Full Text] [PDF]